Journal
PEPTIDES
Volume 54, Issue -, Pages 39-48Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2014.01.002
Keywords
alpha-Lactalbumin; beta-Lactoglobulin; Dipeptidyl peptidase-IV inhibitor; Mode of inhibition; Type 2 diabetes
Funding
- Natural Sciences and Engineering Research Council of Canada (NSERC)
Ask authors/readers for more resources
Inhibition of the enzyme dipeptidyl peptidase (DPP)-IV is one of the strategies used for the treatment of type 2 diabetes. In the present study, pepsin-treated whey protein isolate (WPI) and alpha-lactalbumin displaying DPP-IV inhibitory activity were fractionated by successive chromatographic steps and the resulting active fractions analyzed for their constituent peptides by liquid chromatography-electrospray ionization-tandem mass spectrometry. Among the identified sequences, 24 peptides derived from alpha-lactalbumin and 11 from beta-lactoglobulin were synthesized and their effects on DPP-IV activity assessed. The most potent fragments, LKPTPEGDL and LKPTPEGDLEIL (IC50=45 and 57 mu M, respectively), were found to inhibit DPP-IV in an un-competitive manner. Although several of the peptides tested showed some inhibitory activity, only two were as effective as the un-fractionated WPI hydrolysate and none were as potent as the un-fractionated alpha-lactalbumin hydrolysate. The peptides' structural features, including length and amino acid composition, were found to impact their inhibitory activity. This study provides new insights on the active components responsible for the DPP-IV inhibitory activity of pepsin-treated whey proteins. Copyright (c) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available